Compass Point Research & Trading LLC analystSteve Shawupgraded his investment opinion of Global Medical REIT Inc. to "buy" from"neutral," and increased his price target to $9.25 from $9.

The analyst wrote in a research report: "We upgrade ourrating on shares of GMRE … following the company's 4Q16 results and acquisitionupdate. GMRE was slower to deploy capital out of the gate as a public company,but investment activity is picking up steam. Management expects to closeapproximately $109M of volume in 1H17 while we were previously estimating $80Mof acquisitions. We also now look for $50M of acquisitions in the second halfof the year. The stock is currently trading at a 11% discount to our 2017E NAV,while healthcare peers trade at a 5% premium."